1. Home
  2. CBAN vs IMMP Comparison

CBAN vs IMMP Comparison

Compare CBAN & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Colony Bankcorp Inc.

CBAN

Colony Bankcorp Inc.

HOLD

Current Price

$20.93

Market Cap

396.8M

Sector

Finance

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$2.62

Market Cap

426.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBAN
IMMP
Founded
1975
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
396.8M
426.9M
IPO Year
1998
N/A

Fundamental Metrics

Financial Performance
Metric
CBAN
IMMP
Price
$20.93
$2.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
104.3K
196.3K
Earning Date
01-28-2026
02-26-2026
Dividend Yield
2.30%
N/A
EPS Growth
16.83
N/A
EPS
1.59
N/A
Revenue
$127,681,000.00
$3,306,742.00
Revenue This Year
$33.81
$292.48
Revenue Next Year
$5.43
N/A
P/E Ratio
$13.17
N/A
Revenue Growth
13.59
31.28
52 Week Low
$13.99
$1.32
52 Week High
$21.46
$3.53

Technical Indicators

Market Signals
Indicator
CBAN
IMMP
Relative Strength Index (RSI) 77.04 41.01
Support Level $18.32 $2.69
Resistance Level $21.46 $3.23
Average True Range (ATR) 0.62 0.15
MACD 0.21 -0.07
Stochastic Oscillator 83.12 3.23

Price Performance

Historical Comparison
CBAN
IMMP

About CBAN Colony Bankcorp Inc.

Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: